Cargando…

Systemic Inflammation Index and Tumor Glycolytic Heterogeneity Help Risk Stratify Patients with Advanced Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Treated with Tyrosine Kinase Inhibitor Therapy

SIMPLE SUMMARY: Patients with advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma have been known to respond to first-line tyrosine kinase inhibitor (TKI) treatment. However, a subgroup of patients are non-responsive to the treatment, with poor survival outcomes, and those w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lue, Kun-Han, Huang, Chun-Hou, Hsieh, Tsung-Cheng, Liu, Shu-Hsin, Wu, Yi-Feng, Chen, Yu-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773680/ https://www.ncbi.nlm.nih.gov/pubmed/35053473 http://dx.doi.org/10.3390/cancers14020309

Ejemplares similares

Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors
por: Chang, Bee-Song, et al.
Publicado: (2022)

Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer
por: Chen, Yu-Hung, et al.
Publicado: (2023)

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments
por: Zhao, Xiayan, et al.
Publicado: (2020)

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018)

Acute stimulation of glycolytic flux in cultured primary astrocytes by the tyrosine kinase inhibitor tyrphostin 23
por: Blumrich, Eva-Maria, et al.
Publicado: (2015)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
por: Yamauchi, Mai, et al.
Publicado: (2012)

Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
por: Qiao, Xiaojuan, et al.
Publicado: (2015)

Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
por: Chang, Yoon Soo, et al.
Publicado: (2016)

Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Nishimatsu, Kanako, et al.
Publicado: (2021)

T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma
por: Mirtavoos-Mahyari, Hanifeh, et al.
Publicado: (2022)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

Entrainment of heterogeneous glycolytic oscillations in single cells
por: Gustavsson, Anna-Karin, et al.
Publicado: (2015)

ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition
por: Ju, H-Q, et al.
Publicado: (2017)

Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
por: Kim, Eun-Young, et al.
Publicado: (2013)

Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma
por: Zhu, Jing, et al.
Publicado: (2020)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma
por: de Biase, Dario, et al.
Publicado: (2017)

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
por: Park, Hyung Kyu, et al.
Publicado: (2017)

Identification of a novel gene signature of lung adenocarcinoma based on epidermal growth factor receptor-tyrosine kinase inhibitor resistance
por: Zhou, E., et al.
Publicado: (2022)

Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
por: Heid, Irina, et al.
Publicado: (2022)

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases
por: Lee, Hsin-Hua, et al.
Publicado: (2019)

Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report
por: SUN, QIONG, et al.
Publicado: (2014)

Effects of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeted combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage IV lung adenocarcinoma
por: Kun, Yanxiao, et al.
Publicado: (2023)

Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase
Publicado: (1995)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation
por: Mariotti, Evan T, et al.
Publicado: (2014)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Tbx15 Defines a Glycolytic Subpopulation and White Adipocyte Heterogeneity
por: Lee, Kevin Y., et al.
Publicado: (2017)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
por: Zhang, Lijuan, et al.
Publicado: (2021)

Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Chen, Chien-Hung, et al.
Publicado: (2019)

Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Associated Clostridioides difficile Infection Among Patients with Lung Cancer
por: Chung, Ying-Shan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b5kp4br0rhue9hfs82qjrvaltt